PURPOSE: Conditionally Replicative Adenovirus (CRAd) has been previously demonstrated to augment the activity of radiation, resulting in synergy of cell kill. However, previous models combining radiation with CRAd have not focused on the methods of radiation delivery. MATERIALS AND METHODS: We model the combination of a novel prostate-specific CRAd, Ad5 PSE/PBN E1A-AR (Ad5: adenovirus 5; PSE: prostate-specific enhancer; PBN: rat probasin promoter; E1A: early region 1A; AR: androgen receptor), with radiation delivered both acutely and continuously, in an effort to better mimic the potential clinical modes of prostate cancer radiotherapy. RESULTS: We demonstrate that pre-treatment of cells with acute single high dose rate (HDR) radiation 24 hours prior to viral infection results in significantly enhanced viral replication and virus-mediated cell death. In addition, this combination causes increased level of gamma-H2AX (Phosphorylated histone protein H2AX on serine 139), a marker of double-stranded DNA damage and an indirect measure of nuclear fragmentation. In contrast, continuous low dose rate (LDR) radiation immediately following infection of the same CRAd results in no enhancement of viral replication, and only additive effects in virus-mediated cell death. CONCLUSIONS: These data provide the first direct assessment of the real-time impact of radiation on viral replication and the first comparison of the effect of radiation delivery on the efficacy of CRAd virotherapy. Our data demonstrate substantial differences in CRAd efficacy based on the mode of radiation delivery.
PURPOSE: Conditionally Replicative Adenovirus (CRAd) has been previously demonstrated to augment the activity of radiation, resulting in synergy of cell kill. However, previous models combining radiation with CRAd have not focused on the methods of radiation delivery. MATERIALS AND METHODS: We model the combination of a novel prostate-specific CRAd, Ad5 PSE/PBN E1A-AR (Ad5: adenovirus 5; PSE: prostate-specific enhancer; PBN: rat probasin promoter; E1A: early region 1A; AR: androgen receptor), with radiation delivered both acutely and continuously, in an effort to better mimic the potential clinical modes of prostate cancer radiotherapy. RESULTS: We demonstrate that pre-treatment of cells with acute single high dose rate (HDR) radiation 24 hours prior to viral infection results in significantly enhanced viral replication and virus-mediated cell death. In addition, this combination causes increased level of gamma-H2AX (Phosphorylated histone protein H2AX on serine 139), a marker of double-stranded DNA damage and an indirect measure of nuclear fragmentation. In contrast, continuous low dose rate (LDR) radiation immediately following infection of the same CRAd results in no enhancement of viral replication, and only additive effects in virus-mediated cell death. CONCLUSIONS: These data provide the first direct assessment of the real-time impact of radiation on viral replication and the first comparison of the effect of radiation delivery on the efficacy of CRAd virotherapy. Our data demonstrate substantial differences in CRAd efficacy based on the mode of radiation delivery.
Authors: E Querido; P Blanchette; Q Yan; T Kamura; M Morrison; D Boivin; W G Kaelin; R C Conaway; J W Conaway; P E Branton Journal: Genes Dev Date: 2001-12-01 Impact factor: 11.361
Authors: E Querido; M R Morrison; H Chu-Pham-Dang; S W Thirlwell; D Boivin; P E Branton; M R Morisson Journal: J Virol Date: 2001-01 Impact factor: 5.103
Authors: Victor W van Beusechem; Jacques Grill; D C Jeroen Mastenbroek; Thomas J Wickham; Peter W Roelvink; Hidde J Haisma; Martine L M Lamfers; Clemens M F Dirven; Herbert M Pinedo; Winald R Gerritsen Journal: J Virol Date: 2002-03 Impact factor: 5.103
Authors: T L DeWeese; H van der Poel; S Li; B Mikhak; R Drew; M Goemann; U Hamper; R DeJong; N Detorie; R Rodriguez; T Haulk; A M DeMarzo; S Piantadosi; D C Yu; Y Chen; D R Henderson; M A Carducci; W G Nelson; J W Simons Journal: Cancer Res Date: 2001-10-15 Impact factor: 12.701
Authors: Laurence Maggiorella; Eric Deutsch; Valérie Frascogna; Nicole Chavaudra; Laurence Jeanson; Fabien Milliat; François Eschwege; Jean Bourhis Journal: Cancer Res Date: 2003-05-15 Impact factor: 12.701
Authors: Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers Journal: Nat Med Date: 2003-12-21 Impact factor: 53.440
Authors: S J Advani; J M Markert; R F Sood; S Samuel; G Y Gillespie; M Y Shao; B Roizman; R R Weichselbaum Journal: Gene Ther Date: 2011-05-05 Impact factor: 5.250
Authors: Sean M O'Cathail; Tzveta D Pokrovska; Timothy S Maughan; Kerry D Fisher; Leonard W Seymour; Maria A Hawkins Journal: Front Oncol Date: 2017-07-24 Impact factor: 6.244
Authors: T J Johnson; N Höti; C Liu; W H Chowdhury; Y Li; Y Zhang; S E Lupold; T Deweese; R Rodriguez Journal: Cancer Gene Ther Date: 2013-06-14 Impact factor: 5.987
Authors: Séan M O'Cathail; Steven Davis; Jane Holmes; Richard Brown; Kerry Fisher; Leonard Seymour; Richard Adams; James Good; David Sebag-Montefiore; Tim Maughan; Maria A Hawkins Journal: Radiat Oncol Date: 2020-06-12 Impact factor: 3.481